Skip to content
Screener

Sarepta Therapeutics, Inc. SRPT Q1 2026 earnings

Reported May 6, 2026 · After market close

Revenue$730.8MBeat by $256.6M
EPS$3.16Beat by $2.18
Revenue estimate$474.2M
EPS estimate$0.98

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$354.7M
EPS estimate$0.17

Financials

Q1 2026

Income statement

See full
Revenue$730.8M-1.9%
Net income$331.0M+174%

Balance sheet

See full
Cash & equivalents$464.5M+92.8%
Total debt$198.5M-3.4%
Total equity$1.5B+26.5%
Total assets$3.2B-8.3%

Cash flow

See full
Operating cash flow-$202.7M+65.3%
CapEx$2.1M-95.2%
Free cash flow-$204.8M+67.3%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$2.28B-63.1%
Enterprise value$2.02B-67.2%
P/E35.1×—
P/S1×—

Profitability

See full
Net margin3%—

Returns & leverage

See full
Return on equity4.8%+2.6pp
Debt / equity0.1×0.0×
Current ratio4.6×+0.6×

Segments

By segment

See full
All Other Segments$730.8M-1.9%

FAQ

When did Sarepta Therapeutics, Inc. report Q1 2026 earnings?
Sarepta Therapeutics, Inc. (SRPT) reported Q1 2026 earnings on May 6, 2026 after market close.
What were Sarepta Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Sarepta Therapeutics, Inc. reported revenue of $730.8M and eps of $3.16 for Q1 2026.
Did Sarepta Therapeutics, Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $474.2M by $256.6M. EPS beat the consensus estimate of $0.98 by $2.18.
How did Sarepta Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 1.9% from $744.9M a year earlier.
Where can I find Sarepta Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-208966) and the 10-Q periodic report (0001193125-26-208893) directly on SEC EDGAR. The filing index links above go to sec.gov.